An analysis on recombinant AAV (rAAV) manufacturing economics maps dose-costs by indication and evaluates capacity needs across six major targets. The study estimates cost drivers for gene therapy scaled to prevalence and indication-specific dosing assumptions, covering RPE65 retinal dystrophy, AMD, hemophilia A and B, SMA, and Duchenne muscular dystrophy. The report’s key contribution is an indication-by-indication framing of rAAV affordability and supply constraints, aiming to identify where cost-cutting strategies may have the biggest impact. For payers and developers, dose economics can influence pricing, patient access, and manufacturing investment plans. With gene therapy platforms facing capacity and cost scrutiny, the analysis serves as a quantitative baseline for how supply planning might need to adapt as more targets enter clinical and commercial phases.